Policy & Regulation
Emmes acquires Orphan Reach
13 May 2021 -

Clinical Research Organisation (CRO) and a portfolio company of Behrman Capital, Emmes which is dedicated to supporting the advancement of public health and biopharmaceutical innovation announced on Wednesday that it has acquired UK-based Orphan Reach, a CRO specialised in clinical research related to rare diseases.

Financial terms of the transaction were not revealed. Orphan Reach founder and CEO Thomas Ogorka and the present management of Orphan Reach are to continue in their present roles. This marks Emmes' second acquisition since Behrman's investment in 2019, and is claimed to build on its recent acquisition of Neox S.R.O. in December 2020.

According to Emmes, the transaction expands its geographic presence and complements Neox's operations in central and eastern Europe. It also bolsters the firm's efforts with commercial biopharmaceutical customers and further augments its capabilities in rare diseases.



Related Headlines